Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Aduro Biotech Inc (ADRO) USD0.0001

Sell:$1.10 Buy:$1.11 Change: $0.03 (2.65%)
NASDAQ:0.73%
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
Sell:$1.10
Buy:$1.11
Change: $0.03 (2.65%)
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
Sell:$1.10
Buy:$1.11
Change: $0.03 (2.65%)
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.

Contact details

Address:
740 Heinz Ave
BERKELEY
94710-2748
United States
Telephone:
+1 (510) 8484400
Website:
www.aduro.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ADRO
ISIN:
US00739L1017
Market cap:
$87.76 million
Shares in issue:
80.51 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Stephen Isaacs
    Chairman of the Board, President and Chief Executive Officer
  • Celeste Ferber
    Senior Vice President, General Counsel, Secretary
  • Blaine Templeman
    Chief Administrative Officer and Chief Legal Officer
  • Andrea van Elsas
    Chief Scientific Officer
  • Daniel Hoth
    Interim Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.